Oxidative stress in plasma from maple syrup urine disease patients during treatment.
about
Profiling of oxidative stress in patients with inborn errors of metabolism.Branched-chain amino acid metabolism: from rare Mendelian diseases to more common disorders.Protein phosphatase 2Cm is a critical regulator of branched-chain amino acid catabolism in mice and cultured cells.Advances and challenges in the treatment of branched-chain amino/keto acid metabolic defects.Oxidative stress in phenylketonuria: what is the evidence?Neurological damage in MSUD: the role of oxidative stress."Classical organic acidurias": diagnosis and pathogenesis.Serum Markers of Neurodegeneration in Maple Syrup Urine Disease.Intracerebroventricular administration of α-ketoisocaproic acid decreases brain-derived neurotrophic factor and nerve growth factor levels in brain of young rats.L-carnitine Prevents Oxidative Stress in the Brains of Rats Subjected to a Chemically Induced Chronic Model of MSUD.In vivo neuroprotective effect of L-carnitine against oxidative stress in maple syrup urine disease.Effect of Blood Phenylalanine Levels on Oxidative Stress in Classical Phenylketonuric Patients.Neuroprotective Effect of Creatine and Pyruvate on Enzyme Activities of Phosphoryl Transfer Network and Oxidative Stress Alterations Caused by Leucine Administration in Wistar Rats.Evaluation of dynamic thiol/disulphide homeostasis as a novel indicator of oxidative stress in maple syrup urine disease patients under treatment.Apoptotic signaling pathways induced by acute administration of branched-chain amino acids in an animal model of maple syrup urine disease.Acute and long-term effects of intracerebroventricular administration of α-ketoisocaproic acid on oxidative stress parameters and cognitive and noncognitive behaviors.Altered Redox Homeostasis in Branched-Chain Amino Acid Disorders, Organic Acidurias, and Homocystinuria.
P2860
Q34043194-5ACA102A-27EB-41E8-8A87-BFC2C09E5E07Q34222287-7BCB22D2-F9E6-476B-9248-11EC796869D4Q37209211-40396976-3AFC-4F2D-81B1-14BE4592E5B4Q37835047-46805135-C54A-485E-AF91-AFE27EAB1E40Q37868451-F14141E8-DEE2-4824-A8BE-74961B71F040Q38162092-5CE6E78E-63A5-4E91-A6FF-538E879DDF60Q38950531-0A390096-C0EA-4930-90D3-E1848B3BA9AEQ39359596-DEA97261-E6F5-44EA-A1E8-CEDAADEBCB2DQ40300205-205A2B54-7201-49B0-8049-D1245E7B1D45Q40364430-4818E841-EDD6-4F42-B543-EDD777788A63Q46129559-A4B3C1FC-4002-4067-8989-6CAD66062CCDQ47559946-A107C602-C549-40C0-93CC-87F223444B54Q47694590-3839C9A8-A6D0-4209-8A1E-E845B4F25655Q48565329-6ABB1157-CC7C-4047-BC03-2D4579844DE5Q48578226-DE09F4CB-6225-43B4-AD0E-5DCABC17192AQ50581992-A03AE060-CD05-4AF0-A21F-B7A81F6E6898Q54944181-36B3253A-D09F-476A-8DD9-DF7A1582989B
P2860
Oxidative stress in plasma from maple syrup urine disease patients during treatment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Oxidative stress in plasma from maple syrup urine disease patients during treatment.
@en
Oxidative stress in plasma from maple syrup urine disease patients during treatment.
@nl
type
label
Oxidative stress in plasma from maple syrup urine disease patients during treatment.
@en
Oxidative stress in plasma from maple syrup urine disease patients during treatment.
@nl
prefLabel
Oxidative stress in plasma from maple syrup urine disease patients during treatment.
@en
Oxidative stress in plasma from maple syrup urine disease patients during treatment.
@nl
P2093
P2860
P1476
Oxidative stress in plasma from maple syrup urine disease patients during treatment
@en
P2093
Amanda T Barden
Angela Sitta
Carlos S Dutra-Filho
Carmen R Vargas
Marion Deon
Moacir Wajner
P2860
P2888
P356
10.1007/S11011-007-9077-Y
P577
2007-11-17T00:00:00Z